Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.73), $0.02 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.